Ross Systems - 1500% in einem halben Jahr

Ross Systems ist die derzeit erfolgreichste Aktie an der Nasdaq.
Sie ist aus dem Nichts von 0,25 Cent auf mittlerweile 11 Dollar gestiegen.
Leider habe ich keine Position bei 4 Dollar aufgebaut, nachdem ich mir die
Homepage von Ross angeschaut habe.
http://www.rossystem.com/  

Jetzt gehe ich aber ins Bett.  

Ob das ein "toller" NM pennystock auch mal hinbekommt? Und wenn ja welcher?

Gruss Mio.
 

Immer noch vom allerfeinsten, aber auch markteng, nicht jedermanns Sache.

Tue Dec 17   8.95   13,500   8.49   7.82 - 9.00  
Mon Dec 16   8.42   41,702   8.25   8.10 - 9.00  
Fri Dec 13   7.96   4,000   7.93   7.85 - 8.01  
Thu Dec 12   7.90   2,000   7.86   7.86 - 7.97  
Wed Dec 11   7.91   20,100   7.85   7.85 - 7.92  
Tue Dec 10   7.90   32,200   7.95   7.75 - 7.95  


Gruss E.  

was ist mit Telesens ???  

Ross Systems bei 10,85. 24 % für Eski, ATH in Sicht.

Gruss E.  

Da bin ich mir sicher,vieleicht nicht der kurze Zeitraum aber da gehen die in.


mfg AIDA  

Noch sind die billisch!
Bald evtl. bullish.
Dann hoffentlich teurisch.  

Dann ist der Chart klarer. Ansonsten finde ich keinen Gefallen mehr an Schaufeln und
Schüppen für die Biotechindustrie.
Dann schon lieber XOMA, wenn se noch mal richtig billig sind.

Gruss E.  

Aktien, die jeden Tag teurer werden, bzw. die weggekauft werden wie warme Semmeln.
Eine dieser fantastischen Stories ist NVGN.
Diese australische Firma gehört im Moment zum heissesten Play an der Nasdaq überhaupt.
Die Nachrichtenlage ist hervorragend, der Chart auch.

Gruss E.



Australian Patent Granted to Novogen Covering its Skin Repair Compound NV-07a Patent Means Novogen Now Has Protection in the U.S. and Australia  


STAMFORD, Conn., Jan 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- The
Australian patent has been granted to Novogen (Nasdaq: NVGN) for its topical
skin repair compound, NV-07a, covering protection of the skin from sun-induced
immunosuppression and UV-induced damage.

The effects of sun damage to the skin are major medical and cosmetic issues in
Australia. NV-07a has been developed to repair the skin after damage caused by
prolonged exposure to sunlight.

Changes in the skin due to prolonged exposure to sunlight can lead to structural
damage resulting in wrinkling and photo-aging. These changes can also cause
pronounced suppression of the normal skin immune activity and at the same time
damage to the DNA of skin cells.

Together, these effects predispose to the development of skin cancers.

NV-07a has been shown to restore immune function and inhibit the DNA changes
that may occur, even when used after sun exposure.

Professor Alan Husband, Novogen's Research Director, said while sun block creams
had been the mainstay of skin protection from acute effects of sun exposure,
they had not reduced the incidence of certain types of skin cancer.

"We have demonstrated in human studies and previously in animals that topical
application of NV-07a after sun exposure can prevent these deleterious changes
in the skin and this is a technology which will revolutionize skin care
formulations," Professor Husband said.

Novogen has announced results from two human clinical trials in which
immunosuppression and ongoing DNA damage were both ameliorated in the skin of
human subjects who had been administered a topical skin cream containing NV-07a
after sun exposure.

Mr. Christopher Naughton, Novogen's CEO, said the Australian patent is a
valuable addition to the worldwide patenting programsurrounding NV-07a. The U.S.
patent was granted in late 2002, and further international patents are in
process.

"NV-07a is an exciting commercial opportunity and its value is underwritten by
the success of our aggressive intellectual property and patenting strategy," he
said.

Novogen coordinates and manages its international research and development
programs utilizing the expertise and clinical research capabilities of
universities and hospitals both in Australia and in key international locations.

Novogen's pharmaceutical drug discovery and development portfolio includes the
anti-cancer drug phenoxodiol, and the NV-04 cardiovascular drug program, both
undergoing human clinical trials. More information can be found at
http://www.novogen.com .

CONTACT: Warren Lancaster of Novogen Limited, +1-203-327-1188, ext. 10, or David
Sheon, +1-202-518-6321, for Novogen Limited

SOURCE Novogen Limited




 

Ich verstehe nicht, warum Macropore nicht
länger richtig anziehen, nach diversen guten
News. Ob die fundamental ok sind, weiß ich
allerdings nicht.
Xoma hingegen werden aktuell eher nicht billiger ;-)
 

Das hab ich doch prima erkannt vor einem Monat, Ross holt wieder Schwung.

Gruss E.



Ross Systems, Inc. Estimates 2nd Quarter Profit 19% Increase in Software License Growth More than Doubles Per Share Earnings  


ATLANTA, Jan 15, 2003 /PRNewswire-FirstCall via COMTEX/ -- Ross Systems, Inc.
(Nasdaq: ROSS), a leading provider of world class enterprise management software
and e-business solutions for mid-market process manufacturers, announced today
that it expects a profit of $0.45 diluted earnings per share (EPS) for its
second fiscal quarter of 2003, which ended December 31, 2002. Revenues for the
quarter are estimated to exceed $12.0 million. The quarter's results reflect
positive operating earnings, which further improved over the sequential quarter.
Software license revenue improved 19% over the prior year same quarter while
expense management resulted in further improvements in both operating margins
and net earnings. Estimates are based upon preliminary results and are subject
to final review. "We are pleased with our growth in software license revenue and
new customer sales worldwide," said J. Patrick Tinley, Chairman and CEO of Ross
Systems. "We also achieved overall growth in total revenue as many new customers
began implementation." The Company is scheduled to announce the results for the
quarter ending December 31, 2002 on February 4, 2003, after completion of
routine quarterly review procedures by its external auditors.

About Ross Systems

Ross Systems Inc., listed as NASDAQ: ROSS since 1991, is a global supplier of
business software solutions designed specifically for food and beverage, life
sciences, chemicals, metals, natural products and other process manufacturers.
The company's iRenaissance family of software solutions is a comprehensive,
modular suite including enterprise resource planning (ERP II), human resources,
financials, materials management, manufacturing and distribution, supply chain
management (SCM), customer relationship management (CRM), electronic commerce,
business intelligence and analytics. Designed for process manufacturers and
implemented by more than 1,000 customers worldwide, iRenaissance collaborative
business applications enable companies to leverage the Internet to optimize the
management of internal operations and external channels with suppliers,
distributors, brokers and customers. Ross Systems has more than 25 offices
around the world to serve its customers. For more information, contact Ross via
telephone at (770) 351-9600 by e-mail at info@rossinc.com; or visit
www.rossinc.com .



 

300% seit Oktober 02, wer bietet mehr?

Gruss E.